QPPV.COM KNOWLEDGE ASSESSMENT

Somatrogon: Classification, Mechanism, Growth Hormone Use and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Somatrogon: Classification, Mechanism, Growth Hormone Use and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which outcome measure is generally more informative than a single height measurement when evaluating long-term response to somatrogon?

Height velocity assessed over time The child’s height on one randomly selected day The number of pen colours used The presence or absence of one transient injection-site symptom

Question 2 of 10 A pharmacovigilance professional is reviewing a case involving somatrogon and initially classifies it as an antibody-mediated immune-targeted therapy. What is the most appropriate correction?

The classification is appropriate because all recombinant proteins are monoclonal antibodies Somatrogon should be assessed as a recombinant growth-hormone product with fusion-protein characteristics Somatrogon should be classified as a vaccine because it contains a modified protein Somatrogon should be classified primarily as a corticosteroid because it affects glucose metabolism

Question 3 of 10 Which governance practice is most important when somatrogon is administered across home settings and multiple healthcare interfaces?

Maintain traceability and communication across caregivers, endocrine clinics, pharmacies and home administration Allow each caregiver to change the weekly dose without documentation Treat device complaints as unrelated to clinical outcomes Discard product and batch information once the injection is completed

Question 4 of 10 Why are a new limp or hip pain particularly important in a child receiving growth hormone?

They may indicate growth-related orthopaedic complications such as slipped capital femoral epiphysis They are specific markers of systemic hypersensitivity They demonstrate that IGF-1 sampling was performed at the wrong time They are expected signs that require no clinical assessment

Question 5 of 10 A caregiver reports administering the weekly dose every week, but the prescribed dose in a heavier child requires two injections. Device review shows that only one injection was repeatedly given. How should this be interpreted?

As confirmed full adherence because at least one injection was administered As a potential partial-dose medication error requiring assessment of clinical consequences As evidence that the child received an excessive dose As an injection-site reaction regardless of symptoms

Question 6 of 10 What is the principal pharmacological innovation that permits once-weekly somatrogon administration?

Permanent activation of the growth hormone receptor after a single dose Replacement of growth hormone signalling with direct stimulation of bone cells Fusion-protein engineering that prolongs systemic exposure Inhibition of renal elimination of endogenous insulin-like growth factor 1

Question 7 of 10 Which record structure would best support longitudinal aggregate review of somatrogon benefit-risk?

Separate one-time records for adverse events with no exposure or growth information A linked record covering growth response, weekly dosing, adherence, IGF-1 timing, endocrine and metabolic findings, and serious events over time Only spontaneous reports of injection-site reactions Only annual product sales data without patient-level clinical context

Question 8 of 10 A child receiving somatrogon develops recurrent severe headaches with vomiting and visual disturbance. Which safety concern should receive priority?

Injection-site atrophy only Intracranial hypertension Isolated scoliosis progression without neurological assessment Expected improvement in growth velocity

Question 9 of 10 Which combination best represents device-related information that should be captured in a somatrogon medication-error report?

Pen strength, number of injections, whether the intended dose was fully delivered and caregiver training Only the patient’s blood pressure at birth Only the product’s therapeutic indication, without administration details The child’s dietary preferences and school attendance only

Question 10 of 10 Which description best characterises somatrogon?

A monoclonal antibody that blocks the growth hormone receptor A recombinant growth-hormone fusion protein engineered for prolonged exposure A synthetic analogue of insulin-like growth factor 1 administered intravenously A chorionic gonadotropin product used to stimulate pubertal development

Somatrogon: Classification, Mechanism, Growth Hormone Use and Pharmacovigilance — Knowledge Assessment

Cookie Settings